Search - tctmd.com

Displaying 281 - 300 of 319

Sort: Relevancy | Date

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Todd Neale

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Michael O'Riordan

August 23, 2016

News Daily News

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Todd Neale

August 04, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2016

Shelley Wood

July 01, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

Michael O'Riordan

January 17, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Advertisement

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

TCTMD’s Top 10 Most Popular Stories for June 2016

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Statins Tied to Lower Mortality, Amputation Risks in PAD

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

TCTMD’s Top 10 Most Popular Stories for January 2016

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content